Catalyst Pharmaceuticals price target raised to $35 from $30 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $35 from $30 and keeps a Buy rating on the shares. The firm views Lupin’s decision to change its Paragraph IV certifications for five of the six Firdapse Orange Book-listed patents to Paragraph III certifications as a positive indicator for the likely outcomes of the remaining cases. While it cannot be assumed that all cases will follow the same path as the Teva settlement, the shared timeline and judge provide reasons for optimism regarding favorable outcomes for Catalyst, the analyst tells investors in a research note.